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Abstract
Background: Antimicrobial resistance is an increasingly serious problem in public health globally. Monitoring
resistance levels within healthcare and community settings is critical to combat its ongoing increase. This study
aimed to describe the rates and molecular mechanisms of mupirocin resistance in clinical Staphylococcus aureus
isolates from Tygerberg Hospital, and to describe its association with strain types.
Methods: We retrospectively selected 212 S. aureus isolates which were identified from blood samples and pus
swabs during the years 2009–2011 and 2015–2017. The isolates were identified using conventional microbiological
methods and genotyping was done using spa typing. Cefoxitin (30 μg) disc diffusion and the two disc strategy
(5 μg and 200 μg) were used to determine susceptibility to methicillin and mupirocin, respectively. Isolates with
high-level resistance were screened for the plasmid mediated genes mupA and mupB by PCR, and sequencing of
the ileS gene was done for all isolates exhibiting low-level resistance to describe the mutations associated with this
phenotype. Chi-square test was used to assess the associations between mupirocin resistance and S. aureus
genotypes.
Results: Of 212 S. aureus isolates, 12% (n = 25) were resistant to mupirocin, and 44% (n = 93) were methicillin
resistant. Strain typing identified 73 spa types with spa t045 being the most predominant constituting 11% of the
isolates. High-level mupirocin resistance was observed in 2% (n = 5), and low-level resistance in 9% (n = 20) of the
isolates. The prevalence of high-level mupirocin resistance amongst MRSA and MSSA was 4 and 1% respectively,
while the prevalence of low-level mupirocin resistance was significantly higher in MRSA (18%) compared to MSSA
(3%), (p = 0.032). mupA was the only resistance determinant for high-level resistance, and the IleS mutation V588F
was identified in 95% of the isolates which showed low-level resistance. A significant association was observed
between spa type t032 and high-level mupirocin resistance, and types t037 and t012 and low-level resistance
(p < 0.0001).
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Conclusion: The study reported higher rates of low-level mupirocin resistance compared to high-level resistance,
and in our setting, mupirocin resistance was driven by certain genotypes. Our study advocates for the continuous
screening for mupirocin resistance in S. aureus in clinical settings to better guide treatment and prescribing
practices.
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Introduction
Staphylococcus aureus is the second most frequent cause
of nosocomial bloodstream infections worldwide [1]. S.
aureus nasal carriage is a risk factor for subsequent infec-
tions, especially amongst surgical and dialysis patients [2,
3], and carriage of methicillin-resistant S. aureus (MRSA)
is a particular problem in these high risk patients due to
the limited therapeutic drugs available to treat post-
operative infections [4]. Consequently, infection preven-
tion strategies such as nasal decolonization are employed
to minimize the occurrence of staphylococcal infection
and reduce the risk of transmission within healthcare
settings [5, 6]. In routine intensive care unit practice,
universal decolonization has proven more effective in re-
ducing nosocomial bloodstream infections caused by
MRSA as well as any other pathogen, compared to a tar-
geted approach [7]. In some settings, routine screening
and decolonisation of MRSA carriers prior to hospital ad-
mission is also practiced [8]. The intranasal application of
the antibiotic mupirocin (2%) 2–4 times daily for 4–7 days
is an effective and affordable strategy for decolonization of
MRSA, used alone or in combination with 4% chlorhexi-
dine gluconate (CHG) based body wash [9, 10]. Mupiro-
cin, also known as pseudomonic acid A, is naturally
produced by Pseudomonas fluorescens, was first isolated in
1971 and first introduced into clinical practice in the
United Kingdom in 1985 [5, 11]. It is also used as a topical
agent to treat localised skin and soft tissue infections [10].
Mupirocin inhibits protein synthesis by binding to the
bacterial isoleucyl-tRNA synthetase enzyme which is
encoded by the ileS gene [11].
Resistance to mupirocin in S. aureus emerged largely
due to long-term, unrestricted and unjustified use [12,
13]. Mupirocin resistance is phenotypically categorized
into two levels based on the minimum inhibitory con-
centration (MIC); low-level resistance with MICs of 8–
256 mg/ml, and high-level resistance with MICs > 512
mg/ml [4, 14]. The molecular mechanism of low-level
mupirocin resistance involves point mutations in the ileS
gene; V588F and V631F are two common mutations as-
sociated with this phenotype [15–17]. High level mupir-
ocin resistance is mediated by the plasmid encoded
genes mupA and mupB, which encode an alternative
isoleucyl-tRNA synthetase (ileS2) that is not targeted by
mupirocin [18, 19].
Mupirocin resistance in S. aureus, especially high-level
resistance, is a serious clinical problem, since it is associ-
ated with failure of decolonization, especially among
MRSA carriers [20]. This is of particular concern for in-
fection prevention and control practices involved in the
management of MRSA outbreaks and in the pre-
admission management of surgical patients to minimize
post-operative MRSA infections [10]. A recent system-
atic review describing mupirocin resistance in Africa
highlighted the scarcity of data and advocated for the
need for surveillance studies to monitor the levels of
mupirocin resistance both in the community and health-
care settings [6]. Screening for mupirocin resistance has
only been carried out in 12 of the 54 African countries,
with an estimated pooled prevalence of 14% resistance
amongst MRSA isolates. Only six studies have been con-
ducted in South Africa reporting prevalences of 7–50%,
4–47%, and 0.9–23%, for overall mupirocin resistance,
low-level and high-level mupirocin resistance, respect-
ively, in MRSA [6]. There is a paucity of data describing
associations between mupirocin resistance and the gen-
etic background of S. aureus in Africa. However, studies
from the United States as well as low-middle income
countries such as Iran have reported associations be-
tween spa types t002, t008, and t064 and mupirocin re-
sistance [21, 22]. Few studies have described mupirocin
resistance in the public healthcare sector in the Western
Cape of South Africa, however, they reported aggregated
data from multiple provinces across South Africa, and
mainly investigated resistance rates in MRSA isolates
[23–25]. Therefore this study aimed to describe the rates
of mupirocin resistance in S. aureus isolates collected at
Tygerberg Hospital, to describe the associations between
mupirocin resistance and the genotypes which are circu-
lating in our setting, and to investigate the molecular
mechanisms of low- and high-level mupirocin resistance.
Methods
This study took place at Tygerberg Hospital, a 1384 bed
tertiary academic hospital that serves a population of
approximately 1.9 million in the Western Cape, South Af-
rica. S. aureus isolates were identified at the National
Health Laboratory Service (NHLS) microbiology labora-
tory as part of the diagnostic investigation of patients pre-
senting to the hospital. Our Biobank was retrospectively
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searched for any S. aureus isolates which had been col-
lected from clinical specimens between the years 2009 and
2017. A subset of these isolates was randomly selected to
be included in this study. Information on the date of col-
lection and the type of clinical specimen were retrieved
from laboratory records. The study was approved by the
Health Research Ethics Committee of Stellenbosch Uni-
versity (Reference number N14/06/065).
Bacterial identification and strain typing
The selected S. aureus isolates were identified by stand-
ard microbiological methods such as Gram morphology,
catalase, mannitol fermentation and DNase activity, and
methicillin susceptibility was determined using cefoxitin
disc diffusion, according to the CLSI guidelines [26].
Confirmed S. aureus isolates were stored at − 80 °C. All
S. aureus isolates were genotyped using spa typing as de-
scribed previously [27].
Mupirocin susceptibility testing
The stored isolates were streaked on Tryptone Blood
Agar (Diagnostic Media Products, South Africa). Over-
night cultures were used to perform mupirocin suscepti-
bility testing on Muller-Hinton Sensitivity medium using
two different mupirocin containing discs: a 5 μg disc to
detect low-level mupirocin resistance and a 200 μg disc
to detect high-level mupirocin resistance (Mast diagnos-
tic group, United Kingdom). Zones of inhibition were
interpreted according to the CLSI guidelines [26].
Molecular mechanisms of mupirocin resistance
S. aureus isolates which exhibited high-level mupirocin
resistance were screened for the presence of the plasmid
mediated mupA and mupB genes using the primers and
conditions published previously [28]. For low-level re-
sistance, a 450 bp region in the ileS gene was amplified
using the modified primers mupLL-F1 5’CCGGAAT-
TAAGTTTCCCAGC-3′ and mupLL-R 5′ CAAAGT
TTTCATAGTTGTTAATCGT3’ [29]. Sanger sequen-
cing was done to describe the presence of point muta-
tions within the ileS gene.
Statistical analysis
Statistical analysis was done using STATA version 12
(StataCorp LLC, USA). The difference in the rates of
mupirocin resistance between MRSA and MSSA was de-
termined using z-test. Chi-square test was used to assess
the associations between strain type and mupirocin re-
sistance. Statistical significance was defined as p-values
of < 0.05.
Results
Rates of mupirocin resistance
We included 212 S. aureus isolates based on the avail-
ability in the Biobank. Of these, 93 were collected be-
tween 2009 and 2011, and 119 between 2015 and 2017.
Ninety-two percent (n = 194) of the isolates were from
blood cultures and 8% (n = 18) were isolated from pus
swabs. Forty four percent (n = 93) of the isolates were
MRSA. Strain typing was successful for 180 isolates and
73 spa types were identified.
Mupirocin resistance was observed in 12% (n = 25) of
the isolates; five (2%) and 20 (9%) exhibited high-level
and low-level resistance, respectively. The prevalence of
mupirocin resistance was significantly different between
MRSA (23%; n = 21), and MSSA (3%; n = 4) isolates (p =
0.04) (Fig. 1).
This was consistent for low- and high-level mupirocin
resistance; with low level resistance rates of 18% (n = 17)
among MRSA and 3% (n = 3) among MSSA (p = 0.032),
and high-level mupirocin resistance rates of 4% (n = 4)
and 1% (n = 1) among MRSA and MSSA, respectively
(p < 0.005).
Correlation between mupirocin resistance and strain
types
Figure 2 shows the spa type distribution in the isolate
collection, with spa types identified in ≤2 isolates (n =
100) grouped as “others”. Type t045 was the most com-
mon, representing 11% of isolates, followed by t037
which constituted 7% of the isolate collection. Of the 16
most common spa types (n = 112), six contained only
MRSA isolates (Fig. 2). Mupirocin resistance was repre-
sented in nine different spa types (Table 1). A significant
association was noted between spa types t012 and t037
and low-level mupirocin resistance, while the spa type
t032 was associated with high-level mupirocin resistance
(p < 0.0001). Although all the isolates with spa type t045
were MRSA, they were all mupirocin susceptible. Sev-
enty six percent of susceptible isolates belonged to spa
types in which no resistant isolates were detected (Table
1).
Molecular mechanisms of mupirocin resistance
The mupA gene was detected in all five high-level
mupirocin resistant isolates and the amplification prod-
uct confirmed by Sanger sequencing. mupB was not de-
tected, however the absence could not be confirmed as a
positive control was not available. The absence of mupA
and mupB was also noted in all isolates with low-level
mupirocin resistance. The IleS V588F mutation was de-
tected in 95% (n = 19) of the isolates with low-level re-
sistance. One isolate (spa type t073) carried a possible
novel ileS mutation, S570A.
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Fig. 1 Distribution of mupirocin resistance among S. aureus isolates categorized by methicillin-susceptibility. S: mupirocin susceptible; LL: Low-
level mupirocin resistance; HL: high-level mupirocin resistance. The asterisks show the significant differences in the resistance rates between MSSA
and MRSA. * p-value =0.032, ** p-value < 0.005
Fig. 2 Distribution of the spa types identified in all the clinical S. aureus isolates. The data shown are the percentages of the different spa types.
The asterisks indicate the spa types that contained only MRSA isolates. “Others” represent the spa types with ≤2 isolates
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Discussion
Monitoring the levels of antimicrobial resistance within
healthcare settings is critical to combat the ongoing in-
crease in resistance. In the current study we sought to
describe the rates and molecular mechanisms of mupiro-
cin resistance at Tygerberg Hospital, and to determine
possible associations between mupirocin resistance and
specific S. aureus lineages.
Twelve percent of the isolates selected for this study
exhibited resistance to mupirocin, and the prevalence of
mupirocin resistance was significantly higher in MRSA
(23%) than MSSA (3%). This trend is consistent with
other studies across South Africa; 17% mupirocin resist-
ance was described in MRSA and 2% in MSSA isolates
collected from 13 public academic healthcare centres in
Gauteng, KZN, Free-State and Western Cape in the
years 2010–2012 [24]. The association between MRSA
and resistance to a wide range of other antibiotics is
well-established [30], and is considered a serious prob-
lem due to the limited available therapeutic drugs. In
keeping with this, a study from the private sector in the
Western Cape of South Africa, which investigated S.
aureus isolates from all clinical specimens, reported 28%
mupirocin resistance and a strong association between
methicillin resistance and mupirocin resistance, and
worryingly, co-resistance to mupirocin and fusidic acid
(also a topical antibiotic used for skin infections) [30].
This highlights the need for stewardship of topical anti-
microbial agents. The authors also recommended that in
private healthcare sectors, antibiotic susceptibility testing
should be performed before prescribing mupirocin to
patients. We could not correlate the level of resistance
with the use of mupirocin in our setting due to the lim-
ited access to this information. In our setting, mupirocin
is used primarily for decolonisation as part of the man-
agement of MRSA outbreaks, although it is also
sporadically used as a therapeutic agent for minor skin
infections. This practice is under review as part of the
hospital’s antimicrobial stewardship programme.
We reported only 2% high-level resistance as opposed
to 23% in private healthcare sectors in the Western
Cape, which suggests higher use of mupirocin in the pri-
vate healthcare sector. Conversely, low-level resistance
was 9% in our study compared to 4% in private health-
care sectors [30]. It is worth noting that more than 90%
of the isolates in our study were from blood cultures
compared to only 0.2% in the study from the private sec-
tor, where 77% of the isolates were from skin swabs. Evi-
dence suggest that although invasive and nosocomial
isolates (such as blood cultures) may be associated with
a denser antimicrobial history, their mupirocin resist-
ance rates are lower [23, 30, 31]. Of note, in previous
studies, mupirocin resistance was highly associated
within certain clinical practices such as plastic surgery,
dermatology, and general medicine [30, 31]. Unfortu-
nately, due to the retrospective nature of our study, we
were unable to correlate our isolates with any clinical
practices. This, as well as the issue of the overrepresen-
tation of blood culture isolates should be addressed in
future studies.
Clinically, high-level mupirocin resistance is associated
with decolonization failure, however, recent studies have
shown that low-level resistance is also associated with
reduced effectiveness of mupirocin in eradicating MRSA
carriage [17, 32, 33]. We detected higher rates of low-
level mupirocin resistance than high-level resistance.
The mupA gene was the only resistance determinant ob-
served in the five high-level resistant isolates, which is
consistent with what is commonly described world-wide
[17, 22, 34]. The mupA gene is usually carried on plas-
mids, however a previous study identified a chromosom-
ally encoded mupA gene in isolates with low-level
Table 1 Correlation between S. aureus genotypes and mupirocin resistance
Spa type High-level
N (%)
Low-level
N (%)
Susceptible
N (%)
Molecular mechanism Methicillin resistance P-value
t037 0 (0) 11 (55) 5 (3) V588F MRSA < 0.0001
t012 0 (0) 5 (25) 1 (0.5) V588F MRSA < 0.0001
t032 3 (60) 0 (0) 5 (3) mupA MRSA < 0.0001
t127 1 (20) 0 (0) 0 (0) mupA MSSA –
t1467 1 (20) 0 (0) 0 (0) mupA MRSA –
t891 0 (0) 1 (5) 5 (3) V588F MSSA –
t1517 0 (0) 1 (5) 1 (0.5) V588F MSSA –
t2360 0 (0) 1 (5) 1 (0.5) V588F MSSA –
t073 0 (0) 1 (5) 2 (1) S570A MSSA & MRSA –
Mupirocin susceptible spa types 0 (0) 0 (0) 167 (88.5) – MSSA & MRSA –
Total 5 (100) 20 (100) 187 (100) – – –
Only significant p-values (Chi-square test) are shown in the table.
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resistance [35]. In our study neither mupA nor mupB
were detected in the low-level resistant isolates. The ileS
mutation V588F was the most common mechanism of
low-level resistance, detected in 95% of low level resist-
ant isolates, and is strongly linked to this phenotype
[17]. In-vitro studies have shown that the presence of a
single mutation (including the common ileS V588F) may
have a small effect on bacterial growth rate. These muta-
tions could occur after a single cycle of exposure to
mupirocin, which provides selective pressure for low-
level resistant MRSA strains within settings where
mupirocin is commonly used [16, 17]. This could ex-
plain the high rate of low-level mupirocin resistance in
our setting. A possibly novel ileS mutation, S570A, was
identified in one of the low-level resistant isolates. How-
ever, further investigation is warranted since not all mu-
tations within the ileS gene translate to phenotypic
resistance [17], and only a small region of the ileS gene
was sequenced in this study.
Certain strains were associated with mupirocin resist-
ance; spa types t037 (linked to multilocus sequence type
clonal complex (CC) 8) and t012 (linked to CC5) had
strong associations with low-level resistance (mainly har-
bouring the mutation V588F), and t032 (linked to CC22)
was associated with high-level (mupA) resistance. Stud-
ies within South Africa and even within Africa either did
not correlate strain typing data with mupirocin resist-
ance, or used typing methods which are not comparable
across different laboratories [25, 36, 37]. In Africa, a sin-
gle study from Ghana reported a mupirocin resistant
isolate belonging to the spa type t4805 from a healthcare
worker in Korle Bu Teaching Hospital [38]. In the
United States, low-level resistance was predominantly
reported amongst spa types linked to CC5 and CC8 [21,
39], consistent with the findings of our study. Further-
more, these genetic backgrounds (CC5 and CC8) are
more prone to developing mutations within the ileS even
following a single short treatment course with mupirocin
[17]; which is consistent with the findings of this study.
Conclusion
Although the method of selecting the S. aureus isolates
from the biobank limited our ability to calculate the
overall prevalence of mupirocin resistance, our data pro-
vided a baseline overview of the rates of resistance to
mupirocin at Tygerberg Hospital. We reported high
rates of low-level mupirocin resistance, driven by spa
types t012 and t037, and low rates of high-level resist-
ance, associated with spa type t032. Our study advocates
for the continuous screening for mupirocin resistance in
S. aureus from a wide range of clinical specimens in
order to monitor resistance rates and to inform prescrib-
ing practices.
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